Skip to main content
OpenTrials
Completed

NCT Number: NCT02537314

Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans

The overall hypothesis of this proposal is that nutrient sensing in the foregut regulates metabolic hormone secretion and nutrient metabolism via enteric neural signals, and these mechanisms might be defective in obesity.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

About this study

The study proposes two specific aims Aim 1 will determine if blocking enteric neuronal signaling will alter: a) circulating levels of nutrient substrates and secretion of hormones that regulate nutrient metabolism; and b) glucose and fatty acid absorption, production, and utilization.

Obese (BMI = 30-50 kg/m2) subjects will be studied. The topical anesthetic benzocaine will be infused into the duodenum prior to infusion of glucose and oleic acid into the duodenum. Duodenal infusions with a naso-intestinal feeding tube will circumvent the confounding effects of gastric emptying on the metabolic responses to a meal. Substrates (glucose, free fatty acids), and lipoproteins) and hormones will be measured by standard biochemical and immunological methods. Aim 2 will determine if enteric neural signals regulate appetite. The studies will be carried out in both lean and obese humans and the procedure will be performed as described above. In addition, the subjects will be asked to use a visual analog scale to estimate their level of appetite before, during and after enteral infusions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI 19 - 25 kg/m2 or 30 - 50 kg/m2
  • Age 20 - 50 years

Exclusion criteria

  • Contraindication to a nasoduodenal feeding tube (e.g., deviated nasal septum, prior upper gastrointestinal bleed, or history of easy bleeding)
  • Prior gastric or intestinal surgery or pancreas resection
  • Females with a positive pregnancy test
  • Known history of intestinal diseases including, but not limited to, inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), celiac sprue
  • Type 1 or type 2 diabetes
  • Recent presence of or treatment for gastroenteritis (diarrhea and/or vomiting), constipation, or upper respiratory infection
  • Anemia
  • Abnormal electrocardiogram
  • Prior adverse reaction to anesthesia
  • Tobacco use

Treatment and study plan

Benzocaine

Drug

0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)

Other names: ethyl 4-aminobenzoate

Placebo

Other

Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)

Other names: NaCl, sodium chloride

Primary outcomes

  1. Gastrointestinal Hormones

    Time frame: 5 Hours

    Plasma levels of Cholecystokinin, gastric inhibitory peptide and glucagon like peptide and Ghrelin

  2. Pancreatic Hormones

    Time frame: 5 Hours

    Plasma levels of Insulin, C-peptide, Glucagon

  3. Glucose and Free Fatty Acids

    Time frame: 5 Hours

    Plasma levels

Secondary outcomes

  1. Glucose Metabolism

    Time frame: 5 Hours

    Glucose tracer kinetics ([3-tritiated] glucose and [U-13C-carbon] oleate)

  2. Fat Metabolism

    Time frame: 5 Hours

    Oleate tracer kinetics ([U-13 C-carbon] oleate)

Other outcomes

  1. Appetite, Hunger, and GI symptoms

    Time frame: 5 Hours

    Visual Analog Scales (Likert)

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Important dates

Study start
2015
Primary completion
2022
Study completion
2022
First posted
Sep 1, 2015
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.